title: Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load.
authors.forename: Thijs H
authors.initials: TH
authors.lastname: Oude Munnink
authors.forename: Eli C
authors.initials: EC
authors.lastname: Dijkers
authors.forename: Sabine J
authors.initials: SJ
authors.lastname: Netters
authors.forename: Marjolijn N
authors.initials: MN
authors.lastname: Lub-de Hooge
authors.forename: Adrienne H
authors.initials: AH
authors.lastname: Brouwers
authors.forename: Janny G
authors.initials: JG
authors.lastname: Haasjes
authors.forename: Carolina P
authors.initials: CP
authors.lastname: Schröder
authors.forename: Elisabeth G
authors.initials: EG
authors.lastname: de Vries
mesh_terms: D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011868:Radioisotopes; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000068878:Trastuzumab; D015040:Zirconium
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011868:Radioisotopes; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D015040:Zirconium; C508053:ERBB2 protein, human